EUVIMEDEUVIMED entdecken
Systematische Übersicht

Outcome Measurement Instruments Used to Evaluate Dermatologic Adverse Events in Cancer Trials

Outcome-Messinstrumente zur Bewertung dermatologischer unerwünschter Ereignisse in Krebsstudien

Sheila Shaigany, Nicole Mastacouris, Rachel Tannenbaum, Andrew Strunk, Christopher Luan, Joshua Burshtein, Aaron Burshtein, Richard Carvajal, Amit Garg, Allireza Alloo

JAMA Dermatology · 01.06.2024 · 160 (6) · 651

DOI: 10.1001/jamadermatol.2024.0053 ↗

Auf einen Blick

In 395 Studien wurden Dermatotoxizitäten unter systemischer Krebstherapie meist mit CTCAE erfasst. Patient:innenberichtete Instrumente wurden selten genutzt und die Validität war begrenzt.

Fragestellung

Wie heterogen und wie qualitativ hochwertig sind ClinROMs und PROMs zur Erfassung dermatologischer unerwünschter Ereignisse unter systemischer Krebstherapie?

Methode

Zwei systematische Reviews mit PubMed- und Embase-Suche bis 7. März 2023 bzw. 12. April 2023; Bewertung der Validierungsstudien mit dem COSMIN-Risiko-von-Bias-Tool.

Ergebnisse

395 Studien. CTCAE in 331 Studien (83,8 %). Mindestens 1 hautbezogenes PROM in 79 Studien (20,0 %); am häufigsten DLQI (34) und Skindex-16 (20).

Einschränkungen

Keine Studien zu Inhaltsvalidität, Intrarater-Reliabilität oder Messfehler für CTCAE, DLQI oder Skindex; keine strukturelle Validität, interne Konsistenz und Responsivität für DLQI oder Skindex.

Schlussfolgerung der Autor:innen

Die Autor:innen berichten ein enges Spektrum an ClinROMs und PROMs mit begrenzter Validität zur Messung dermatologischer unerwünschter Ereignisse unter systemischer Krebstherapie.

Kernaussagen

  • CTCAE war das am häufigsten verwendete Instrument (331 Studien; 83,8 %)
  • PROMs wurden selten genutzt; DLQI und Skindex-16 am häufigsten
  • Validierungsdaten waren für mehrere Messgütekriterien unzureichend

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift JAMA Dermatology, erschienen am 01.06.2024. Verfasst von Sheila Shaigany und 9 weiteren Autor:innen. Beteiligte Einrichtung: Northwell Health, New Hyde Park, New York. Hauptthemen laut MEDLINE: Neoplasms, Patient Reported Outcome Measures, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Assessment of type, severity, and impact of dermatologic adverse events (DAEs) necessitates well-developed and validated clinician-reported outcome measures (ClinROMs) and patient-reported outcome measures (PROMs) that evaluate concepts specific to mucocutaneous toxic effects and that allow appropriate interpretation and comparison of DAEs across trials.

Objective

To evaluate heterogeneity and quality of ClinROMs and PROMs used to assess DAEs from systemic cancer therapy. Evidence Review Two systematic reviews were conducted by searching PubMed and Embase databases from inception through March 7, 2023, and April 12, 2023. The first search included randomized clinical trials and observational studies reporting systemic cancer treatment–induced DAEs assessed by a ClinROM or PROM. The second included studies evaluating measurement properties of frequently used ClinROM and PROM instruments. The Consensus-Based Standards for the Selection of Health Measurement Instruments risk of bias tool was used to evaluate methodologic quality of validation assessments.

Findings

A total of 395 studies were included. The Common Terminology Criteria for Adverse Events (CTCAE) was utilized in 331 studies meeting inclusion criteria (83.8%). At least 1 skin-related PROM was infrequently utilized in systemic chemotherapy clinical trials (79 studies [20.0%]). Most frequently utilized PROMs were the Dermatology Life Quality Index (DLQI; 34 studies [8.6%]) and Skindex-16 (20 studies [5.1%]). Among studies capturing DAEs, 115 (29.1%) reported a nondescript term (ie, rash) as the only DAE. Eight studies described 44 property assessments of the CTCAE, DLQI, and Skindex. There were no studies evaluating content validity, intrarater reliability, or measurement error for the CTCAE, DLQI, or Skindex. There were no studies evaluating structural validity, internal consistency, and responsiveness of DLQI or Skindex. Interrater reliability and responsiveness were each assessed for 1 DAE-related component of the CTCAE. Construct validity for CTCAE, DLQI, and Skindex was evaluated in 29 (65.9%), 3 (6.8%), and 9 (20.5%) assessments, respectively. Conclusions and Relevance In this systematic review, there was a narrow spectrum of ClinROMs and PROMs with limited validity for the measurement of DAEs in the context of systemic chemotherapy interventions in clinical trials. Report of trial DAEs often had low morphologic specificity and meaning. Based on existing gaps in measurement and report of DAEs, a frequent and impactful adverse event to chemotherapy, the framework for evaluating cutaneous toxic effects in oncology trials may need collaborative reevaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPatient Reported Outcome MeasuresAntineoplastic AgentsHumansSkin DiseasesOutcome Assessment, Health CareRandomized Controlled Trials as Topic

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Northwell Health, New Hyde Park, New York.
  • Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.
  • Northwell Health Cancer Institute, New Hyde Park, New York.

Zitieren

APA

Shaigany, S., Mastacouris, N., Tannenbaum, R., Strunk, A., Luan, C., Burshtein, J., Burshtein, A., Carvajal, R., Garg, A., & Alloo, A. (2024). Outcome Measurement Instruments Used to Evaluate Dermatologic Adverse Events in Cancer Trials. JAMA Dermatology, 160(6), 651. https://doi.org/10.1001/jamadermatol.2024.0053

Vancouver

Shaigany S, Mastacouris N, Tannenbaum R, Strunk A, Luan C, Burshtein J, et al. Outcome Measurement Instruments Used to Evaluate Dermatologic Adverse Events in Cancer Trials. JAMA Dermatology. 2024;160(6):651. doi:10.1001/jamadermatol.2024.0053

BibTeX
@article{Shaigany2024,
  author = {Shaigany, Sheila and Mastacouris, Nicole and Tannenbaum, Rachel and Strunk, Andrew and Luan, Christopher and Burshtein, Joshua and Burshtein, Aaron and Carvajal, Richard and Garg, Amit and Alloo, Allireza},
  title = {Outcome Measurement Instruments Used to Evaluate Dermatologic Adverse Events in Cancer Trials},
  journal = {JAMA Dermatology},
  year = {2024},
  volume = {160},
  number = {6},
  pages = {651},
  doi = {10.1001/jamadermatol.2024.0053}
}
Kostenlos starten →